| Literature DB >> 26996456 |
Baojing Liu1, Qingqing Du1, Lu Chen1, Guangping Fu1, Shujin Li1, Lihong Fu1, Xiaojing Zhang1, Chunling Ma1, Cong Bin1.
Abstract
The epigenetic modification of mitochondrial DNA (mtDNA) is still in controversy. To clarify this point, we applied the gold standard method for DNA methylation, bisulfite pyrosequencing, to examine human mtDNA methylation status. Before bisulfite conversion, BamHI was used to digest DNA to open the loop of mtDNA. The results demonstrated that the linear mtDNA had significantly higher bisulfite conversion efficiency compared with circular mtDNA. Furthermore, the methylation values obtained from linear mtDNA were significantly lower than that of circular mtDNA, which was verified by SEQUENOM MassARRAY. The above impacts of circular structure were also observed in lung DNA samples but not in saliva DNA samples. Mitochondrial genome methylation of blood samples and saliva samples from 14 unrelated individuals was detected. The detected regions covered 83 CpG sites across mtDNA including D-loop, 12 S rRNA, 16 S rRNA, ND1, COXI, ND3, ND4, ND5, CYTB. We found that the average methylation levels of nine regions were all less than 2% for both sample types. In conclusion, our findings firstly show that the circular structure of mtDNA affects bisulfite conversion efficiency, which leads to overestimation of mtDNA methylation values. CpG methylation in human mtDNA is a very rare event at most DNA regions.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26996456 PMCID: PMC4800444 DOI: 10.1038/srep23421
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Brief information of mtDNA sequences detected by bisulfite pyrosequencing.
| No. of sequence | Domain | Product | Location | CpG Location | CpG number |
|---|---|---|---|---|---|
| MT1 | D-Loop | – | 8–15 | 3–8 | 6 |
| MT2 | D-Loop | – | 463–609 | 14–16 | 3 |
| MT3 | rRNA | s-rRNA(12 S rRNA) | 1182–1398 | 37–39 | 3 |
| MT4 | rRNA | s-rRNA(12 S rRNA) | 1358–1711 | 42–45 | 4 |
| MT5 | rRNA | l-rRNA(16 S rRNA) | 2495–2626 | 64–67 | 4 |
| MT6 | rRNA | l-rRNA(16 S rRNA) | 2767–2915 | 72–76 | 5 |
| MT7 | rRNA | l-rRNA(16 S rRNA) | 2879–3170 | 79–83 | 5 |
| MT8 | protein | NADH dehydrogenase subunit 1 | 3324–3520 | 96–100 | 5 |
| MT9 | protein | NADH dehydrogenase subunit 1 | 3469–3596 | 102–104 | 3 |
| MT10 | Protein | NADH dehydrogenase subunit 1 | 3596–3798 | 106–109 | 4 |
| MT11 | protein | NADH dehydrogenase subunit 1 | 3832–4090 | 114–118 | 5 |
| MT12 | protein | cytochrome oxidase subunit I | 6077–6235 | 169–172 | 4 |
| MT13 | Protein | cytochrome oxidase subunit I | 6920–7107 | 196–199 | 4 |
| MT14 | protein | NADH dehydrogenase subunit 3 | 10088–10307 | 287–293 | 7 |
| MT15 | protein | NADH dehydrogenase subunit 4 | 11712–11837 | 325–327 | 3 |
| MT16 | protein | NADH dehydrogenase subunit 5 | 13878–14045 | 373–375 | 3 |
| MT17 | protein | cytochrome b | 15443–15652 | 414–418 | 5 |
| MT18 | protein | cytochrome b | 15648–15800 | 419–421 | 3 |
| MT19 | D-loop | – | 16045–16222 | 424–426 | 3 |
| MT20 | D-loop | – | 16368–16490 | 429–432 | 4 |
Figure 1The circular structure of mtDNA affects the pyrosequencing pass ratio in blood samples but not in saliva samples.
In blood samples, pyrosequencing pass ratio in linear mtDNA group was significantly higher than that of circular mtDNA group. In saliva samples, there were no significant differences between two groups. *P < 0.01 vs linear mtDNA group.
Comparison of the failure reason of pyrosequencing between BamHI treated group and non-BamHI treated group.
| Failure reason | Non open-loop group | Open-loop group | ||||||
|---|---|---|---|---|---|---|---|---|
| MT1 | MT3 | MT10 | MT13 | MT1 | MT3 | MT10 | MT13 | |
| Blood | ||||||||
| Failed bisulfite conversion | 100%(16/16) | 10%(1/10) | 81.82%(27/33) | 89.19%(33/37) | 0 | 50%(2/4) | 0 | 6.67%(1/15) |
| Lack of data | 0 | 10%(1/10) | 0 | 0 | 28%(7/25) | 0 | 33.33%(1/3) | 13.33%(2/15) |
| Possible dispensation error/Failed reference sequence pattern | 0 | 0 | 0 | 2.70%(1/37) | 72%(18/25) | 0 | 0 | 0 |
| Low signal-to-noise ratio | 0 | 80%(8/10) | 18.18%(6/33) | 8.11%(3/37) | 0 | 50%(2/4) | 66.67%(2/3) | 80%(12/15) |
| Saliva | ||||||||
| Failed bisulfite conversion | 0 | 0 | 0 | 0 | 0 | 66.67%(2/3) | 0 | 0 |
| Lack of data | 50%(1/2) | 0 | 0 | 0 | 100(3/3) | 0 | 0 | 0 |
| Possible dispensation error/Failed reference sequence pattern | 0 | 0 | 0 | 0 | 0 | 33.33%(1/3) | 0 | 0 |
| Low signal-to-noise ratio | 50%(1/2) | 100%(2/2) | 100%(2/2) | 100%(1/1) | 0 | 0 | 100%(1/1) | 100%(2/2) |
Figure 2Comparison of mean methylation level between linear mtDNA group and circular mtDNA group.
Data are represented as mean ± SE, *P < 0.001 vs linear mtDNA group. For blood samples, the mean methylation values in samples of circular mtDNA group were significantly higher than that of linear mtDNA group at all of the detected CpG sites. However, for saliva samples, significant differences were only observed at four CpG sites, and two of them are higher in linear mtDNA group, the other two are just opposite.
D values of methylation levels of the DNA same sample with or without BamHI treatment detected by bisulfite pyrosequencing.
| CpG location | Blood samples | Saliva samples | ||||
|---|---|---|---|---|---|---|
| n | mean ± S/M(QR) | n | mean ± S/M(QR) | |||
| CpG3 | 32 | 7.00(2.00) | 15 | 0.00(0.00) | 0.317 | |
| CpG4 | 32 | 20.19 ± 4.64 | 15 | −0.63 ± 1.47 | 0.117 | |
| CpG5 | 32 | 11.00(4.00) | 15 | 0.00(0.50) | 0.246 | |
| CpG6 | 32 | 16.22 ± 3.56 | 15 | 0.43 ± 2.33 | 0.483 | |
| CpG7 | 32 | 10.00(4.00) | 15 | 0.20 ± 2.30 | 0.741 | |
| CpG8 | 32 | 4.00(1.75) | 15 | 2.37 ± 1.76 | ||
| mean | 32 | 11.50(3.00) | 15 | 0.43 ± 1.15 | 0.166 | |
| CpG37 | 24 | 2.00(3.75) | 14 | −1.00(6.00) | 0.072 | |
| CpG38 | 24 | 1.50(2.00) | 14 | 0.60 ± 2.10 | 0.287 | |
| CpG39 | 24 | 0.00(2.00) | 0.721 | 14 | 1.47 ± 2.03 | |
| mean | 24 | 1.50 ± 1.38 | 14 | 0.47 ± 1.64 | 0.290 | |
| CpG106 | 23 | 6.00(2.00) | 14 | 0.00(2.00) | 0.087 | |
| CpG107 | 23 | 9.00(3.00) | 14 | −0.20 ± 1.31 | 0.563 | |
| CpG108 | 23 | 5.00(2.00) | 14 | 0.00(1.00) | 0.285 | |
| CpG109 | 23 | 3.00(2.00) | 14 | 0.00(1.00) | ||
| mean | 23 | 6.00(2.00) | 14 | 0.00(0.50) | 0.174 | |
| CpG196 | 13 | 9.08 ± 2.47 | 14 | 0.00(0.00) | 0.414 | |
| CpG197 | 13 | 7.00(3.00) | 14 | 0.07 ± 1.59 | 0.873 | |
| CpG198 | 13 | 7.00(1.00) | 14 | 0.00(2.00) | 0.201 | |
| CpG199 | 13 | 6.00(1.00) | 14 | 0.13 ± 1.36 | 0.709 | |
| mean | 13 | 7.00(1.50) | 14 | 0.20 ± 1.15 | 0.510 | |
D values equal to methylation value with BamHI treatment minus without BamHI treatment. D values are represented with mean ± S or M (QR) when D values do not meet normalized distribution.
Comparison of methylation levels of the same blood DNA sample with or without BamHI treatment detected by Sequenom MassARRAY.
| Amplicon name | CpG location | Methylation level (%) | |||
|---|---|---|---|---|---|
| N | Without BamHI treatment | With BamHI treatment | |||
| Sequenom_1 | CpG360 | 14 | 12.57 ± 1.60 | 2.29 ± 0.24 | |
| CpG361 | 14 | 12.57 ± 1.60 | 2.29 ± 0.24 | ||
| CpG362 | 14 | 6.57 ± 0.23 | 1.64 ± 0.25 | ||
| CpG364 | 14 | 4.36 ± 0.32 | 1.43 ± 0.31 | ||
| CpG365 | 14 | 1.21 ± 0.47 | 0.57 ± 0.23 | 0.104 | |
| CpG367 | 14 | 5.29 ± 0.29 | 1.50 ± 0.27 | ||
| CpG368 | 14 | 3.43 ± 0.31 | 1.29 ± 0.27 | ||
| CpG369 | 14 | 4.43 ± 0.23 | 1.00 ± 0.30 | ||
| CpG370 | 14 | 7.29 ± 0.34 | 1.86 ± 0.27 | ||
| CpG371 | 14 | 4.36 ± 0.29 | 1.29 ± 0.35 | ||
| Sequenom_2 | CpG225 | 14 | 27.79 ± 3.32 | 6.86 ± 0.84 | |
| CpG226 | 14 | 5.43 ± 0.17 | 2.92 ± 0.35 | ||
| CpG227 | 14 | 12.29 ± 0.82 | 4.21 ± 0.44 | ||
| CpG228 | 14 | 12.29 ± 0.82 | 4.21 ± 0.45 | ||
| CpG229 | 14 | 2.79 ± 0.21 | 2.00 ± 0.18 | ||
| CpG230 | 14 | 26.21 ± 6.48 | 5.50 ± 0.78 | ||
| CpG231 | 14 | 11.57 ± 0.84 | 4.07 ± 0.46 | ||
| CpG232 | 14 | 11.57 ± 0.84 | 4.07 ± 0.59 | ||
| CpG233 | 14 | 14.14 ± 0.80 | 3.50 ± 0.29 | ||
| CpG235 | 14 | 5.14 ± 0.23 | 3.07 ± 0.46 | ||
| CpG236 | 14 | 13.86 ± 0.49 | 4.50 ± 0.31 | ||
| CpG237 | 14 | 13.86 ± 0.49 | 4.50 ± 0.31 | ||
| CpG238 | 14 | 6.14 ± 0.83 | 3.57 ± 0.39 | ||
| CpG239 | 14 | 3.36 ± 0.31 | 2.00 ± 0.39 | ||
| CpG240 | 14 | 3.36 ± 0.31 | 2.00 ± 0.39 | ||
| CpG241 | 14 | 10.93 ± 1.13 | 2.50 ± 0.31 | ||
| CpG243 | 14 | 4.29 ± 0.52 | 1.86 ± 0.44 | ||
| Sequenom_3 | CpG106 | 14 | 5.93 ± 0.56 | 3.07 ± 0.35 | |
| CpG107 | 14 | 3.71 ± 0.19 | 1.14 ± 0.25 | ||
| CpG108 | 14 | 3.71 ± 0.19 | 1.14 ± 0.25 | ||
| CpG109 | 14 | 3.43 ± 0.92 | 1.07 ± 0.29 | ||
Comparison of methylation levels of the same lung DNA sample with or without BamHI treatment detected by bisulfite pyrosequencing.
| Amplicon name | CpG location | N | Methylation level (%) | ||
|---|---|---|---|---|---|
| Without BamHI treatment | With BamHI treatment | ||||
| MT1 | CpG3 | 7 | 2.86 ± 0.59 | 1.57 ± 0.75 | 0.318 |
| CpG4 | 7 | 5.86 ± 1.06 | 1.43 ± 0.95 | ||
| CpG5 | 7 | 5.57 ± 1.67 | 1.14 ± 0.74 | ||
| CpG6 | 7 | 2.57 ± 1.34 | 1.29 ± 0.84 | 0.620 | |
| CpG7 | 7 | 4.29 ± 0.78 | 2.29 ± 1.13 | 0.073 | |
| CpG8 | 7 | 0.57 ± 0.57 | 2.29 ± 1.11 | 0.318 | |
| Mean | 7 | 4.00 ± 0.95 | 1.57 ± 0.20 | ||
Figure 3Mean methylation values of 9 regions in human mtDNA.
(A) The distribution of regions we detected on human mtDNA were marked as red line outside the mtDNA circle. (B) Mean methylation values of 9 regions in human mtDNA detected by bisulfite pyrosequencing. Data are represented as mean ± SE. *P < 0.01 vs blood samples.